

March 25, 1966

Vincent Y. Cremata, Jr., M.D.
Associate Director
Department of Clinical Pharmacology
Chas. Pfizer & Company, Inc.
Groton, Connecticut 06340

Dear Vince:

Thank you very much for the reports on thiothixene. We are now completing our fifteenth subject, and as soon as we have a satisfactory treatment period, I will summarize our observations. Surely, by now you know that the dosages we have used have been too high. We have exceeded your recommendations, and found that at these higher dosages the secondary effects exceeded the beneficial behavioral changes. All of our patients had the dosages reduced, and, in addition, for those who have developed parkinsonism, we have administered procyclidine.

The EEG patterns as well as the clinical laboratory data are being summarized on a continuing basis, and I trust that this report will be completed by the end of May.

With regard to the compound P-5227, I agree that this is of considerable interest. I would like to undertake such a study. As I am in transition, I cannot make a specific commitment, but will do my best to arrange such a study program either here or in New York.

My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:jmh